As patients with HIV are living longer because of effective treatments, rates of comorbid chronic diseases such as bone complications are increasing. There is a growing body of literature showing increased rates of osteopenia and osteporosis in the HIV population. Less is known about the risk of fracture, as well as other bone complications, such as avascular necrosis (AVN).
INTRODUCTION
Although infection with HIV remains a significant health problem throughout the world, the introduction of effective antiretroviral therapy (ART) regimens has radically shifted the public health implications of the disease. As patients with HIV on treatment are living longer, an increasing number of chronic health problems are occurring in an already vulnerable population; bone complications, such as osteoporosis and avascular necrosis (AVN), are one such area that rheumatologists may begin to see. This study aims to review the current literature on the association of HIV with higher rates of osteoporosis, fracture, and AVN, as well as the possible mechanisms by which the virus can begin to affect bone composition.
OSTEOPOROSIS AND HIV
Research published in the past decade suggests that patients infected with HIV have a higher rate of osteoporosis than the general population. Several cross-sectional studies examining this are summarized in a meta-analysis published in 2006, which reports that the probability of developing osteoporosis is over three times higher in HIV patients as compared with HIV-negative controls [1] . There are animal data suggesting that HIV infection itself can induce bone resorption [2] . However, in humans the association may be complicated by the findings that HIV patients have higher rates of other known osteoporotic risk factors, such as low BMI [3, 4 protease inhibitors are the specific medications that are particularly associated with decrease in BMD. Data from randomized controlled trials show that an ART regimen including tenofovir is associated with significantly decreased BMD at 1 and even 2 years as compared with another NRTI, abacavir [8 & ,9] . In addition, HIV-negative men participating in a trial examining the effects of tenofovir for preexposure prophylaxis experienced a small but significant drop in BMD in men taking the medication [10 & ]. Similarly, protease inhibitors are implicated in decreasing BMD and increased rates of osteoporosis [1, 11, 12] . Analyses of randomized trial data suggest that this bone loss is present as early as 1 year after start of treatment [13] .
Studies with longer follow-up time, however, find that this initial decrease in BMD is attenuated with length of time on ART treatment. For example, a study [14 & ] examining BMD measurements in a small cohort of HIV-positive men on established ART compared to HIV-negative controls finds no significant difference in BMD between the HIV-positive and HIV-negative men at 6 years, except at the lumbar spine where a greater increase is seen in the HIVpositive men. A recent meta-analysis reviewing several longitudinal studies of HIV cohorts demonstrates a decrease in BMD, especially in the first year of treatment, in patients who are untreated at baseline. However, those patients on established ART at baseline have stable BMD throughout follow-up [15] .
HIV AND FRACTURE
Although there is substantial evidence that low BMD is more prevalent in HIV-positive individuals as compared with those who are HIV-negative, the question remains whether this finding translates to an increased risk of fracture (see Table 1 ). One of the first studies examining this outcome is a large hospital-based cross-sectional study [16] which finds increased rates of fractures in HIV-positive patients when compared with HIV-negative patients. Whereas certainly suggestive, this study is unable to address many possible risk factors that could confound this relationship. Subsequent studies [17 & ,18] in both predominantly male as well as female populations demonstrate that it may be an increased burden of traditional osteoporotic risk factors, such as decreased BMI, can at least partially explain this finding of increased risk of fracture in the HIV-positive population rather than the virus itself. Other studies show that in addition to classic osteoporotic risk factors, HIV-specific risk factors such as history of AIDS-defining illness, low CD4 cell counts, or co-infection with hepatitis C are associated with increased rates of fracture [18,19 & ] (see Table 2 ).
The data suggesting ARTs decrease BMD led to an interest in examining the role of ARTs on fracture risk. Table 3 ). These observational studies are difficult to perform because of the inherent difference in the types of patients taking ARTs compared with those who take no ARTs. They also require controlling for numerous classic osteoporotic as well as HIV-specific risk factors.
Information about changes in BMD has increased focus on the possibility that given agents, such as tenofovir and protease inhibitors, may increase fracture risk (see Table 3 ). Cumulative exposure to tenofovir increases osteoporotic fracture risk in a recent cohort study of US Veterans [21 && ]. This same study also suggests increasing risk of fracture with exposure to a certain combination of protease inhibitors, lopinavir/ritonovir. However, a recent claims-based case-control study [20 & ] did not support these findings, and in fact suggests decreasing risk of fracture with longer tenofovir exposure. In light of these conflicting data, further research examining the effect of ART on fracture risk is needed in order to select ART regimens, especially in those who carry other osteoporotic risk factors.
MEASURES TO PREVENT BONE LOSS IN HIV-POSITIVE PATIENTS
There is growing interest in finding potential modifiable factors that could prevent the increase in bone
KEY POINTS
Recent studies suggest that the HIV-positive population is at an increased risk of development of osteoporosis [low bone mineral density (BMD)], which is likely due to many factors. Antiretroviral therapy (ART) has been associated with decreasing BMD, particularly in the first year of therapy, but it is unclear if this early bone loss translates into increased risk of fracture.
There is a need for further trials examining the effects of vitamin D and calcium supplementation in prevention of bone loss in the HIV population, especially in those on specific ART regimens.
Although there is an increased risk of avascular necrosis (AVN) in the HIV-positive population, further studies are needed to determine the role of specific HIV-related risk factors, such as particular ART regimens. In this cross-sectional study, incidence rates could not be calculated. However, prevalence is given for HIVþ population as 28.7 per 1000 patients, and for HIVÀ population is 17.7 per 1000 patients.
loss seen in the HIV-positive population, such as the correction of vitamin D deficiency. Vitamin D deficiency is common in the HIV-positive population, with studies citing 29-73% prevalence, although it is not clear that the rate of deficiency is different than matched HIV-negative controls [24 && ]. In the HIV population, vitamin D deficiency is associated with well known risk factors such as race, as well as HIV-specific factors like CD4 cell count [25, 26] . Particular ART medications may also play a role in vitamin D deficiency; low vitamin D levels are associated with the non-nucleoside reverse transcriptase inhibitor (NNRTI) efavirenz [25, 27] , and tenofovir is associated with elevated parathyroid hormone levels [28,29 & ]. There is no clear evidence that vitamin D repletion improves BMD in the HIV-positive population [24 && ], particularly for those patients on ART regimens that potentially affect vitamin D homeostasis. There is suggestion of benefit in a recent trial randomizing young HIV-positive adults to vitamin D supplementation versus placebo over a 3-month period [30 & ]. This study shows that supplementation of vitamin D significantly decreases parathyroid hormone levels and bone resorption markers, especially in the tenofovir-based regimen arm. However, another trial randomizing HIV-positive children and teens to receive either vitamin D repletion and calcium supplementation or double placebo for 2 years did not find a significant difference in BMD between the two groups [31 & ]. There are currently no published randomized controlled trials supporting vitamin D and calcium supplementation use to prevent BMD loss seen on particular ART regimens in older adult HIV-positive patients, in whom a larger impact may be seen.
Studies [32, 33] show that bisphosphonates improve low BMD in the HIV-positive population, and can be administered safely. Two randomized controlled trials on HIV-positive populations with low BMD found that weekly alendronate in addition to calcium and vitamin D supplementation was not only well tolerated but improved BMD at 48 weeks. Studies [34, 35] examining the use of zoledronic acid in patients with HIV and low BMD found similar safety and efficacy. However, it remains unknown if there is a utility in prescribing bisphosphonates in HIV-positive patients as preventive therapy, in order to avert the decrease in BMD seen during initiation of ART, and potentially decrease fractures.
HIV AND AVASCULAR NECROSIS
The effect of HIV on bone is not limited to low BMD and fracture; in the past decade studies show an association between HIV infection and risk of development of AVN (see Table 4 ). Incidence of symptomatic AVN in the HIV-positive population is reported as high as 0.3-3.4/1000 person-years [36] [37] [38] , as compared to the general population in which reports of AVN are 0.03-0.04/1000 personyears [39, 40] . A small study [41] examining bilateral hip MRI on asymptomatic patients with HIV found the prevalence of AVN to be 4.4% (15/339) as compared with 0% (0/118) in HIV-negative controls matched on age and sex. Unlike the osteoporosis and HIV literature, there is, however, a paucity of data linking AVN with risk factors specific to HIV and its treatment. Initial case reports link AVN to initiation of protease inhibitors [42, 43] . However, this association is not supported in subsequent case-control studies, and instead associations are found with known risk factors of AVN, for example, steroid use and hyperlipidemia [44, 45] . One large French case-control study suggests an association of AVN with HIV-specific factors, such as a history of AIDS-defining illness, as well as with use of a combination of three or more ART medications. In this study [36] , the relative risk of AVN attributable to taking combination ART for less than 12 months compared with no ART is 2.6 [95% confidence interval (CI) 1.2-5.9], but rises to 5.1 (95% CI 2.1-12.6) in those being treated for over 60 months. Further research is needed to validate these findings in another cohort, as well as determine whether a particular ART regimen, such as the one including protease inhibitors, is associated with development of AVN as this may help guide therapeutic choices for patients with other classic risk factors for AVN.
OSTEOIMMUNOLOGY AND RELATION WITH HIV
In recent years, research is illuminating the relationship between a chronic inflammatory state and changes in bone metabolism. Chronic inflammation and persistently elevated cytokines, for example, tumor necrosis factor (TNF) or interleukins, appear to activate proteins like receptor activator of nuclear factor kappa-B ligand (RANKL), which in turn activates osteoclasts that resorb bone. The effect of these inflammatory molecules on bone degradation begins to explain the mechanism by which medications such as TNF-inhibitors not only decrease inflammation in patients with diseases like rheumatoid arthritis, but decrease formation of erosions as well [46] . Although we often consider these changes in the setting of inflammatory arthritis, studies suggest the effect of inflammation on bone occurs in the general population as well -for example, high-sensitivity C-reactive protein (CRP) is associated with increased rate of fracture [47] .
A persistent inflammatory state secondary to infection with HIV may also detrimentally effect bone composition. Elevation in inflammatory proteins such as CRP and TNF-a is associated with HIV infection, but there are conflicting data in regards to whether inflammatory markers decrease with treatment for HIV [48, 49] . Research continues to elucidate how inflammatory markers are activated in the face of B and T-cell dysfunction due to HIV, in addition to the effect HIV infection has directly on bone. A recent review by Ofotokun et al. [50 && ] describes research suggesting that HIV infection increases expression of certain pro-osteoclast proteins such as RANKL, and decreases expression of other proteins that regulate the activation of osteoclasts, such as osteoprotegerin, which is an inactivator of RANKL. These complex associations may begin to explain the effects of HIV infection on bone metabolism, and perhaps why patients with HIV may be at an increased risk of osteoporosis.
CONCLUSION
Rheumatologists are well versed in seeing patients with systemic inflammation. Although not a rheumatologic illness per se, HIV is becoming a chronic disease that is also associated with systemic inflammation. This inflammation may play a role in bone complications such as osteoporosis and fracture. HIV presents a difficult clinical situation; in addition to the systemic inflammation and HIV infection itself there are increased rates of several risk factors of bone complications, such as increased comorbidities, higher rates of co-infection with hepatitis C, and the potential effects of ART on bone. As research on the association of bone disease and HIV continues to grow, we will not only likely learn more about the complicated interplay of potential risk factors seen in the HIV-positive population but also may gain knowledge regarding the effect a systemic chronic illness has on bone which could be extrapolated to the general population. 
